To Get Full Access :

Voranigo

Voranigo is an oral treatment for adults and teens with Grade 2 astrocytoma or oligodendroglioma that carry an IDH1 or IDH2 mutation, used after surgery. It blocks mutant IDH enzymes to slow tumor progression, significantly extending the time before disease worsens

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Vorasidenib
  • Innovator :

    SERVIER PHARMACEUTICALS LLC
  • Approval Date :

    06-Aug-24
  • NCE-1 Date :

    06-Aug-28
  • NCE Date :

    06-Aug-29
  • Dosage Form :

    Oral Tablets
  • Strength :

    10 mg and 40 mg
  • Therapeutic Category :

    Anticancer
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    102
  • 2026 :

    134
  • 2027 :

    156
  • 2028 :

    167
  • 2029 :

    173
  • 2030 :

    177
  • 2031 :

    183
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?